Cited by 190Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsFerroptosis and cancer prognosis

The DOI matches its Crossref record; 180 of the 184 references it cites were found in a registry or an index.

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Open access

Qiao, Meng, Jiang, Tao, Liu, Xinyu, Mao, Shiqi, Zhou, Fei, Li, Xuefei, Zhao, Chao, Chen, Xiaoxia, Su, Chunxia, Ren, Shengxiang, Zhou, Caicun·2021·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2021.04.003

Open this paper in CoChat — free account

Abstract

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-1/programmed cell death ligand-1 axis have significantly shifted the treatment paradigm in advanced NSCLC, clinical benefits of these agents are limited in patients with EGFR-mutated NSCLC. Several predictive biomarkers (e.g., programmed cell death ligand-1 expression, tumor mutation burden), which have been validated in EGFR-wild type NSCLC, however, are not efficacious in EGFR-mutated tumors, suggesting the unique characteristics of tumor microenvironment of EGFR-mutated NSCLC. Here, we first summarized the clinical evidence on the efficacy of ICIs in patients with EGFR-mutated NSCLC. Then, the cancer immunogram features of EGFR-mutated NSCLC was depicted to visualize the state of cancer-immune system interactions, including tumor foreignness, tumor sensitivity to immune effectors, metabolism, general immune status, immune cell infiltration, cytokines, and soluble molecules. We further discussed the potential subpopulations with EGFR mutations that could benefit from ICI treatment. Lastly, we put forward future strategies to adequately maximize the efficacy of ICI treatment in patients with EGFR-mutated NSCLC in the upcoming era of combination immunotherapies.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2021.04.003

Cites

180 of 180 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citation
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Exosomes: composition, biogenesis and function
Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature reviews. Immunology · doi:10.1038/nri855 · Cited by 5,355

Flagged first, then by citations

Show all 184 references

4 of the 184 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

Garon, 2015, Prior TKI therapy in NSCLC EGFR mutant patients associates with lack of response to anti-PD-1 treatment, J Thorac Oncol, 10
Qiao, 2021, MA13.06 Deciphering the characteristics of tumor microenvironment in EGFR-mutated non-small cell lung cancer, J Thorac Oncol, 16
Le, 2019, Abstract 5028: Characterization of the tumor immune microenvironment in treatment-nave EGFR-mutant NSCLC uncovers a low IFN-gamma suppressive immune phenotype, Proceedings: AACR Annual Meeting

Sorted by citations

Items 101–190 of 190

The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer
Shen, Z., Teng, M., Han, L., Bian, D., Zhang, J., Zhu, X., Qing, Y., Hu, S., Chen, Y., Yao, W., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03560-x · Cited by 4
Refining neoadjuvant immunotherapy for resectable lung cancer
Shields, M. D., & Lovly, C. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-03001-x · Cited by 4
Tumor Mutation Signature Reveals the Risk Factors of Lung Adenocarcinoma with EGFR or KRAS Mutation
Wang, J., Guo, C., Wang, J., Zhang, X., Qi, J., Huang, X., Hu, Z., Wang, H., & Hong, B. (2025) · Cancer Control · doi:10.1177/10732748241307363 · Cited by 5
Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis
Zhang, W., Xiong, J., Li, Y., Nie, J., Zhao, W., Guo, Z., Liu, X., Zhang, Q., Chen, X., Li, Y., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251338046 · Cited by 4
Self-citation
EGFR-TKI combination treatment for NSCLC with EGFR-sensitive mutation
Wu, Y., Yh, L., Onzere, L. E., Quan, W., Zhang, X., & Ma, J. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2520962 · Cited by 6
Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer
Zhao, J., Zhuang, W., Sun, B., Bai, H., Wang, Z., Zhong, J., Wan, R., Liu, L., Duan, J., & Wang, J. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15295 · Cited by 4
[Retracted] Treatment Protocols in the Efficacy and Safety of Anti‐EGFR Medicines in Combination with Standard Therapy for Patients with Nasopharyngeal Cancer: A Meta‐Analysis
Fang, Y., Fan, J., & Yan, C. (2023) · BioMed Research International · doi:10.1155/2023/9477442 · Cited by 4
Retracted
Testing the plasticity-first theory of tumor evolution with spatiotemporal lineage tracingPreprint
Yang, J., Hou, L., Wang, X., Zhang, N., Bian, Y., Lu, Z., Chen, Y., Xie, D., Fang, Y., Wang, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.06.668639 · Cited by 4
Expression and clinical significance of programmed cell death protein 1/programmed death-ligand 1 in non-small cell lung cancer patients with rare mutations of epidermal growth factor receptor gene: A retrospective cohort study
Du, Y., Zhuang, Z., Zong, L., & Xu, Y. (2025) · CytoJournal · doi:10.25259/cytojournal_136_2024 · Cited by 3
Comprehensive analysis of single-cell and bulk RNA sequencing data reveals an EGFR signature for predicting immunotherapy response and prognosis in pan-cancer
Ye, C., Chen, X., Chen, Z., Liu, S., Kong, R., Lin, W., Zhu, M., Sun, X., & Xu, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604394 · Cited by 4
Self-citation
Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC
Song, L., Zeng, L., Xu, Q., Li, Y., Guo, W., Lin, S., Jiang, W., Wang, Z., Deng, L., Huang, Z. H., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113211 · Cited by 3
[Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].
Li, J., Yao, X., Qiu, L., Zhang, R., & Wang, G. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.101.17 · Cited by 3
Case Report: Benefits of a NSCLC Patient With EGFR A289G/F287_G288insHA cis Mutations From Immunotherapy in Combination With Antiangiogenesis and Chemotherapy and Sequential Treatment of EGFR-TKI
Zhang, H., Dong, W., Zhao, H., Hu, Y., You, X., Sun, T., & Xiao, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.826938 · Cited by 3
Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma
Jiang, G., Miao, Y., Wang, Z., Zhang, Q., Zhou, P., & Zhang, F. (2023) · Aging · doi:10.18632/aging.204535 · Cited by 3
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
Shang, X., Zhang, W., Han, W., Xia, H., Liu, G., Wang, X., & Liu, Y. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02707-x · Cited by 3
Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study
Wu, W., Yu, S., Huang, J., Qi, Q., Wu, Y., & Dong, J. (2024) · BMC Cancer · doi:10.1186/s12885-024-12773-x · Cited by 3
Real-World Efficacy and Safety of Atezolizumab for Advanced Non-Small Cell Lung Cancer in Japan: A Retrospective Multicenter Analysis
Okada, M., Ohgino, K., Horiuchi, K., Sayama, K., Arai, D., Watase, M., Kobayashi, K., Terashima, T., Ishioka, K., Miyawaki, M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247815 · Cited by 3
The impact of tislelizumab immunotherapy on multiple primary lung cancer presenting as ground-glass nodules: preliminary results analysis from a single-arm, phase II trial
Wu, J., Fu, X., Gao, Y., Qin, S., Xiong, J., Qu, R., & Cai, Y. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04212-y · Cited by 2
Predicting PD-L1 expression in advanced EGFR-mutant lung adenocarcinoma patients using NECT, CECT radiomics and clinical features
Li, J., Yang, Z., Liu, L., Tang, F., Zheng, T., Zhang, C., Peng, Y., Yang, Z., Zhou, Z., Tan, B., et al. (2026) · BMC Cancer · doi:10.1186/s12885-025-15514-w · Cited by 2
Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis
Wang, Y., Zhang, L., Zhan, J., Wen, L., Zhao, X., Sun, H., Chen, X., Zhang, Y., Chen, G., Zhao, Y., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.108914 · Cited by 2
Self-citation
Bispecific T-cell Engager (CD3 × EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor–Refractory NSCLC
Guo, H., Wang, Y., Diao, M., Han, R., He, T., Wu, Y., Wang, Q., Cheng, L., Zhao, C., Li, X., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103607 · Cited by 2
Self-citation
Blood Based Biomarkers for Predicting Treatment Response to Immune Checkpoint Inhibitors After EGFR ‐ TKI Resistance in Non‐Small Cell Lung Cancer
Park, M. S., Lim, J. H., Park, N., Park, E., Lim, A., Lee, S., Cho, Y., Kwak, S., Lee, M. H., Seo, D., et al. (2026) · Thoracic Cancer · doi:10.1111/1759-7714.70257 · Cited by 2
The Role of the Ecto-Nucleotidases CD73 and CD39 in Chemo- and Immunotherapy
Mucha, P. T., Brahmachari, A., Frańczak, M., Tomczyk, M., Kutryb-Zając, B. A., Koszałka, P., Giovannetti, E., & Peters, G. J. (2026) · Cancers · doi:10.3390/cancers18060957 · Cited by 3
An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer
Zhou, Y., Yin, Y., Xu, J., Xu, Z., Yang, B., He, Q., Luo, P., Yan, H., & Yang, X. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2221786 · Cited by 2
[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].
Liu, Y., & Miao, J. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.26 · Cited by 2
Case report: A lung squamous cell carcinoma patient with a rare EGFR G719X mutation and high PD-L1 expression showed a good response to anti-PD1 therapy
Zhu, Z., Bao, X., Shi, H.-Y., & Gu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1283008 · Cited by 2
Effects of combined sintilimab and chemotherapy on progression-free survival and overall survival in osteosarcoma patients with metastasis
Fan, L., Zhang, D.-B., Ma, Y., Song, Y., & Duan, X.-L. (2024) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.40.4.8536 · Cited by 2
Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma
Torasawa, M., Yoshida, T., Shiraishi, K., Yagishita, S., Ono, H., Uehara, Y., Miyakoshi, J., Tateishi, A., Igawa, Y. S., Higashiyama, R. I., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108494 · Cited by 2
Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials
Meyers, D. E., Rittberg, R., Dawe, D. E., & Banerji, S. O. (2024) · Current Oncology · doi:10.3390/curroncol31090407 · Cited by 2
Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
Sun, S., Han, J., Liu, W., Wu, Z., Zhao, X. Q., Yan, X., Jiao, S., & Fang, J. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i18.6069 · Cited by 2
NAPSB as a Predictive Marker for Prognosis and Therapy Associated with an Immuno-Hot Tumor Microenvironment in Hepatocellular CarcinomaPreprint
Zhao, Q., Ning, Y., Lin, K., Liu, X., Ding, Y., Jiang, X., Zhang, Z., Xuan, Y.-T., Liu, L., Wang, F., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1417814/v1 · Cited by 2
Self-citation
PD-1 blockade augments CD8+ T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer
Nakasuka, T., Ohashi, K., Nishii, K., Hirabae, A., Okawa, S., Tomonobu, N., Takada, K., Ando, C., Watanabe, H., Makimoto, G., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.01.018 · Cited by 1
Pembrolizumab in Combination With Platinum-Based Chemotherapy in Patients With Recurrent EGFR and ALK Gene Altered Non-Small-Cell Lung Cancer (NSCLC)
Gadgeel, S. M., Nagasaka, M., Dziubek, K., Braun, T., Hassan, K. A., Cheng, H., Halmos, B., Wozniak, A. J., Stevenson, J. P., Patil, P. D., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.09.002 · Cited by 1
From “undruggable” to tractable: Therapeutic advances targeting Kristen rat sarcoma viral homolog glycine to cysteine mutation at codon 12 (KRAS G12C)-mutant cancers and emerging resistance mechanisms
Devanahally, S., & Dubey, S. (2026) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2026.02.001 · Cited by 2
A Multidisciplinary Approach to Checkpoint Inhibitor Adverse Reactions
Andrews, C. N., Mukherjee, E. M., Gibson, A., Postow, M. A., Phillips, E. J., & Johnson, D. B. (2026) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2026.02.027 · Cited by 1
The Role of PD-L1 in Treatment Decision-Making for Perioperative EGFR-Mutated Lung Cancer and its Genomic Analysis
Qi, Y., Qiu, Z., Huang, W., Zhang, C. J., Fu, R., Jie, G., Yang, X.-W., Lin, Y.-D., Li, H.-J., Cui, Q., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19781-0 · Cited by 1
Clinical significance of spread through air spaces according to EGFR mutation status in lung adenocarcinoma
Hashinokuchi, A., Kosai, K., Haratake, N., Fujishita, T., Shimamatsu, S., Kometani, T., Kawabata, T., Toyozawa, R., Taguchi, K., Shimokawa, M., et al. (2026) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyag129 · Cited by 1
Durable clinical response to immunotherapy in EGFR-mutated lung adenocarcinoma with squamous cell carcinoma transformation and high expression of PD-L1 after resistance development: A case report
Peng, Z., & Xu, Y. (2022) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2022.100199 · Cited by 1
Cerric ammonium nitrate catalyzed eco-friendly green synthesis of chitosan Schiff base using PEG-400 as an anticancer agent against gastric cancer cells via inhibiting EGFR
Geng, W., Feng, X., Li, C., & Ni, S. (2024) · Bulletin of the Chemical Society of Ethiopia · doi:10.4314/bcse.v38i4.22 · Cited by 1
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18
Choi, D.-H., Kim, M., Kim, Y. S., Park, K. U., Cho, J. H., Kim, H.-S., Lee, K. H., Ahn, H., Kim, I. H., Lee, K. H., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100734 · Cited by 1
Recent advances in nanoparticles with a PD-L1-based therapy combination of chemotherapy for lung cancer
Shareef, A., Sameer, H. N., Yaseen, A., Athab, Z. H., Adil, M., & Allela, O. Q. B. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104872 · Cited by 1
A retrospective analysis of immunotherapy in non-small cell lung cancer patients with targetable genetic mutations
Zhang, S., Liu, J., Liu, J., & Lu, K. (2025) · Medicine · doi:10.1097/md.0000000000044144 · Cited by 1
Prognostic Factors of Nintedanib-docetaxel in Patients with Previously Treated Non-small-cell Lung Cancer
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Pacheco-Barcía, V., Palka-Kotlowska, M., Saez-Bertrand, C., & Blasco-Guerrero, M. (2023) · Journal of Cancer Immunology · doi:10.33696/cancerimmunol.5.077
Single-Cell RNA Sequencing Reveals Tumor Microenvironment Remodeling after Neoadjuvant Immunotherapy in Non-small Cell Lung CancerPreprint
Hu, J., zhang, L., Xia, H., Yan, Y., Zhu, X., Sun, F., Sun, L., Li, S., Li, D., Wang, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-934132/v1
NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma NAPSB predicts prognosis and therapy in HCCPreprint
Ning, Y., Lin, K., Liu, X., Ding, Y., Jiang, X., Zhang, Z., Xuan, Y.-T., Li, D., Liu, L., Wang, F., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1549285/v1
Self-citation
Efficacy of immunochemotherapy compared with platinum-based chemotherapy and immunotherapy after tyrosine kinase inhibitor failure in advanced non-small cell lung cancer patients with EGFR mutationPreprint
Hata, T., Sakaguchi, C., Hirano, K., Kobe, H., Ishida, M., Nakano, T., Tachibana, Y., Murai, J., Enomoto, M., Tanaka, T., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1590589/v1
Application of Informatics Tools to Facilitate the Practice of Precision Medicine with Genomic Testing and Clinical Data
Sayer, M. (2023) · Chapman University Digital Commons (Chapman University) · doi:10.36837/chapman.000424
Four Prognostic Related Genes Were Identified by Bio-Informatics Analysis as Key Genes in Lung AdenocarcinomaPreprint
Sha, X., Li, H., Wang, G., Li, Z., Wang, W., Zhang, P., Liu, L., Cao, T., Wang, S., Zhou, Y. L., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4654714
Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR ‐ TKI Treatment: A Retrospective Cohort Study
Su, Y., Tey, S., Lee, C., Lin, C., Tsai, J., Lin, C., & Kuo, C. (2025) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.70023
Anti-lung cancer activity of lotusine in non-small cell lung cancer HCC827 via reducing proliferation, oxidative stress, induction of apoptosis, and G0/G1 cell cycle arrest via suppressing EGFR-Akt-ERK signalling
Lan, Y., Sun, J., Xu, J., & Chen, X. (2025) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-025-01048-9
Self-citation
Impact of platinum-based adjuvant chemotherapy on the effectiveness of IB–IIIA non-small cell lung adenocarcinoma with varying EGFR mutation statuses: a propensity score matching analysis
Xiao, Y., Wang, Z., Yang, X., Wang, N., Deng, X., & Xu, G. (2025) · Journal of Thoracic Disease · doi:10.21037/jtd-2025-107
Targeting the amino acid metabolism in Lung Sarcopenia: A Systems Engineering ApproachPreprint
Kumar, G., Khandibharad, S., & Singh, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.30.662260
Efficacy and safety of the optimal immunochemotherapy regimen for resectable non-small cell lung cancer: A network meta-analysis of randomized controlled trials
Zeng, J., Yi, B., Chang, R., Li, J.-S., Yu, Z., Liu, K.-F., & Gao, Y. (2025) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2025.07.166
Evaluation of NTRK3 mutation and a mutation-based gene set as biomarkers for immunotherapy outcomes in multiple cancersPreprint
Huang, J., Liang, J., Wang, K., Lei, K., Liang, R., Lei, J., & Cai, S. (2025) · Research Square · doi:10.21203/rs.3.rs-7437970/v1
Lung cancer genetics in bridging chemotherapy with advanced therapies for precision oncology
Khan, Z., Musambil, M., & Khan, I. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33302-6.00012-3
Additional file 4 of Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO
Wen, S., Peng, W., Chen, Y., Du, X., Xia, J., Shen, B., & Zhou, G. (2022) · Figshare · doi:10.6084/m9.figshare.19205852
Additional file 1 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
Shang, X., Zhang, W., Han, W., Xia, H., Liu, N., Wang, X., & Liu, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24669938
Additional file 3 of Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO
Wen, S., Peng, W., Chen, Y., Du, X., Xia, J., Shen, B., & Zhou, G. (2022) · Figshare · doi:10.6084/m9.figshare.19205849
Additional file 6 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
Shang, X., Zhang, W., Han, W., Xia, H., Liu, N., Wang, X., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26647272
Additional file 2 of Decoding temporal heterogeneity in NSCLC through machine learning and prognostic model construction
Cheng, J., Xiao, M., Meng, Q., Zhang, M., Zhang, D. X., Liu, L., Jin, Q., Fu, Z., Li, Y., Chen, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26036502
Self-citation
Additional file 6 of Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO
Wen, S., Peng, W., Chen, Y., Du, X., Xia, J., Shen, B., & Zhou, G. (2022) · Figshare · doi:10.6084/m9.figshare.19205858
Additional file 5 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
Shang, X., Zhang, W., Han, W., Xia, H., Liu, N., Wang, X., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26647269
Additional file 5 of Decoding temporal heterogeneity in NSCLC through machine learning and prognostic model construction
Cheng, J., Xiao, M., Meng, Q., Zhang, M., Zhang, D. X., Liu, L., Jin, Q., Fu, Z., Li, Y., Chen, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26733322
Self-citation
Additional file 4 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
Shang, X., Zhang, W., Han, W., Xia, H., Liu, N., Wang, X., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26647266
Additional file 2 of Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO
Wen, S., Peng, W., Chen, Y., Du, X., Xia, J., Shen, B., & Zhou, G. (2022) · Figshare · doi:10.6084/m9.figshare.19205846
Additional file 5 of Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO
Wen, S., Peng, W., Chen, Y., Du, X., Xia, J., Shen, B., & Zhou, G. (2022) · Figshare · doi:10.6084/m9.figshare.19205855
Additional file 3 of Decoding temporal heterogeneity in NSCLC through machine learning and prognostic model construction
Cheng, J., Xiao, M., Meng, Q., Zhang, M., Zhang, D. X., Liu, L., Jin, Q., Fu, Z., Li, Y., Chen, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26733316
Self-citation
Additional file 1 of EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer
Huang, H., Zhu, X., Yu, Y., Li, Z., Yang, Y., Xia, L., & Lu, S. (2024) · Figshare · doi:10.6084/m9.figshare.26301137
Additional file 4 of Decoding temporal heterogeneity in NSCLC through machine learning and prognostic model construction
Cheng, J., Xiao, M., Meng, Q., Zhang, M., Zhang, D. X., Liu, L., Jin, Q., Fu, Z., Li, Y., Chen, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26733319
Self-citation
Additional file 3 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
Shang, X., Zhang, W., Han, W., Xia, H., Liu, N., Wang, X., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26647263
Additional file 1 of Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO
Wen, S., Peng, W., Chen, Y., Du, X., Xia, J., Shen, B., & Zhou, G. (2022) · Figshare · doi:10.6084/m9.figshare.19205840
Additional file 1 of ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma
Zhang, W., Shang, X., Liu, N., Ma, X., Yang, R., Xia, H., Zhang, Y., Zheng, Q., Wang, X., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26556251
Additional file 1 of Decoding temporal heterogeneity in NSCLC through machine learning and prognostic model construction
Cheng, J., Xiao, M., Meng, Q., Zhang, M., Zhang, D. X., Liu, L., Jin, Q., Fu, Z., Li, Y., Chen, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26036369
Self-citation
Additional file 2 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
Shang, X., Zhang, W., Han, W., Xia, H., Liu, N., Wang, X., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.24670377
The Application and Research Progress of Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer
常, 艳. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15102935
New activities of homoyessotoxin against lung cancer through the regulation of EGFR/PI3K/AKT pathway
Chen, K., Gao, X., Li, J., Jia, S., Jiang, X., Zhou, J., & Xie, W. (2026) · Marine Life Science & Technology · doi:10.1007/s42995-026-00354-9
Exploring synergistic therapeutic potential of Erlotinib and artemisinin in non-small cell lung Cancer (NSCLC) using pharmacological networking and mathematical modeling
Suleman, F., Khan, T., Alshehade, S. A., Ali, M., Irfan, H. M., Shahzad, A., Zarzour, R. H. A., & Rasool, S. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.120890
Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study)
Shibaki, R., Akamatsu, H., Okada, M., Murotani, K., Osuga, M., Nishino, K., Murakami, S., Wakuda, K., Mitsudomi, T., 弘人, 多., et al. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.100967
ROCK1 inhibition primes anti-tumor immunity in EGFR-mutant NSCLC by triggering PD-L1 degradation mediated by SMURF2
Bai, M., Gao, Q., Jin, P., Ma, L., Li, J., Wu, L., Wang, W., Lv, L., Li, Y., Cheng, B., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02653-2
Targetable driver gene–tumor immune microenvironment axis in non-small cell lung cancer: from molecular pathological mechanisms to precision immunotherapy stratification strategies
Chen, W., Zhang, F., & Zheng, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1801943
Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr ‐mutated lung cancer
Nishimura, J., Kuribayashi, T., Braegelmann, J., Okawa, S., Taoka, M., Mori, S., Nishimura, T., Tanaka, T., Makimoto, G., Ninomiya, K., et al. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70264
The advanced research of immunotherapy in Epidermal growth factor receptor mutation-positive non-small cell lung cancer
He, X. L., Tian, T., Ma, Y., Cai, Q., Deng, G., Zhang, X., & Liang, N. (2026) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1981_25
The ADAMTS8 paradox: Context-dependent mechanisms linking tumor suppression and cardiovascular remodeling
Cai, Y., Wang, M., Qiu, R., Liu, S., Liu, T., & Wang, G. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102311
Machine learning and molecular docking identify the anti-tumor activity of lobetyolin in non-small cell lung cancer by targeting the oncogenic factor GART
Xu, M., Zhong, L., Yang, N., & Gao, Y. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100429
CD39+CD8+ T cell infiltration is associated with clinical outcomes of subsequent immunotherapy in advanced EGFR-mutant non-small cell lung cancer
Lu, W., Wu, Q., Wang, Z., Cheng, Q., Zuo, X., Liu, X., Lv, J., Song, Y., Zhang, F., & Lv, T. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261458240
Self-citation
Crosstalk Between Immunometabolic Pathways in Non-Small Cell Lung Cancer
Khilwani, R., Gulhane, P., Tukrul, M., Rani, D., Kumar, G., Goswami, S., & Singh, S. (2026) · Immunological Investigations · doi:10.1080/08820139.2026.2698754
Real‐World Outcomes of Consolidation Durvalumab After Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: A Retrospective Cohort Study From Vietnam
Tran, H. T., Hung, K. D., Nguyen, H. T. T., Nguyen, H. T. N., Nguyen, P. T. B., Dao, T. M., Nguyen, T. V., Nguyen, T. A., Hằng, Đ. N., & Hoang, N. B. (2026) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.70148
Ability of KBTBD10 to inhibit non-small cell lung cancer mediated by LINC01585
Jiang, X., Guan, J., Liang, K., Li, Q., & Sun, L. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117336
Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.
Chen, X.-R., Liang, J.-Q., Zhu, J.-K., Huang, X.-L., Hu, Y.-D., Lin, Z.-W., & Zhan, C. (2026) · Biochimica et biophysica acta. Reviews on cancer · doi:10.1016/j.bbcan.2026.189709
Self-citation
Granzyme B PET Imaging Reveals Lgmn + Macrophage‐Mediated Immune Evasion and Guides Immunotherapy in EGFR‐TKI‐Resistant NSCLC
Wang, D., Luo, W., Liu, Q., Tang, W., Zhu, B., Chen, J., Zhou, Q., Tang, S., Xu, X., & Song, S. (2026) · Advanced Science · doi:10.1002/advs.77837

Authors: Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., & Zhou, C.
Affiliations: Tongji University (CN)
Corresponding author: Zhou, Caicun
ORCID: Qiao, Meng
Jiang, Tao
Liu, Xinyu
Mao, Shiqi
Zhou, Fei
Li, Xuefei
Zhao, Chao
Chen, Xiaoxia
Su, Chunxia
Ren, Shengxiang
Zhou, Caicun
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2021-08
Volume: 16
Issue: 8
Pages: 1267-1288
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2021.04.003
OpenAlex: W3159640891
Cited by: 186
References: 184
Citations by year: 2026: 24 · 2025: 39 · 2024: 39 · 2023: 35 · 2022: 35 · 2021: 14
FWCI: 3.85
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Natural Science Foundation of China (81871865, 81972167)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords: immune checkpoint inhibitors, EGFR-mutant non-small cell lung cancer, PD-1/PD-L1 axis, predictive biomarkers, tumor mutational burden, PD-L1 expression, tumor microenvironment, immune cell infiltration, cytokines, combination immunotherapy, treatment response
MeSH terms: Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Biomarkers, Tumor, Tumor Microenvironment, B7-H1 Antigen, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks